Cdk2 Inhibitors
Items 41 to 50 of 53 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cdk/Crk Inhibitor | 784211-09-2 | sc-203872 | 1 mg | $290.00 | ||
Cdk/Crk Inhibitor acts as a potent modulator of Cdk2, characterized by its ability to form stable complexes through unique hydrogen bonding and hydrophobic interactions. This compound induces a significant alteration in the enzyme's tertiary structure, which disrupts substrate recognition. Its reaction kinetics suggest a non-competitive inhibition pattern, influencing the phosphorylation cascade. Furthermore, the inhibitor's distinct molecular architecture enhances selectivity towards specific protein interactions, thereby fine-tuning cellular signaling dynamics. | ||||||
AT7519 | 844442-38-2 | sc-364416 sc-364416A sc-364416B sc-364416C | 5 mg 10 mg 100 mg 1 g | $207.00 $246.00 $1025.00 $3065.00 | 1 | |
AT7519 is a potent CDK inhibitor that targets CDK2 and other kinases, inducing cell cycle arrest and apoptosis by preventing substrate phosphorylation. | ||||||
CR8, (S)-Isomer | 1084893-56-0 | sc-311307 | 5 mg | $201.00 | ||
CR8, (S)-Isomer, exhibits remarkable specificity in its interaction with Cdk2, primarily through its unique steric configuration that facilitates precise binding. This compound alters the enzyme's active site conformation, leading to a notable decrease in catalytic efficiency. Its kinetic profile reveals a mixed inhibition mechanism, impacting both substrate affinity and turnover rate. Additionally, CR8's unique electronic properties contribute to its selective engagement with key regulatory motifs, modulating cellular pathways with high precision. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $242.00 $871.00 | 1 | |
Dinaciclib is a CDK2/9 inhibitor that disrupts cell cycle progression and transcription by inhibiting phosphorylation of CDK2 substrates and RNA polymerase II. | ||||||
TAK 165 | 366017-09-6 | sc-361372 sc-361372A | 10 mg 50 mg | $139.00 $781.00 | ||
TAK 165 demonstrates a distinctive binding affinity for Cdk2, characterized by its ability to stabilize an inactive conformation of the enzyme. This compound engages in specific hydrogen bonding and hydrophobic interactions, effectively disrupting the enzyme's catalytic cycle. Its reaction kinetics indicate a competitive inhibition pattern, influencing substrate binding dynamics. Furthermore, TAK 165's unique structural features allow it to selectively modulate downstream signaling pathways, showcasing its intricate role in cellular regulation. | ||||||
Cdk2/9 Inhibitor Inhibitor | 507487-89-0 | sc-221411 | 5 mg | $416.00 | 1 | |
Cdk2/9 Inhibitor exhibits a remarkable selectivity for Cdk2, engaging in unique electrostatic interactions that alter the enzyme's active site conformation. This compound effectively impedes the phosphorylation process by stabilizing a non-productive enzyme-substrate complex. Its kinetic profile reveals a non-competitive inhibition mechanism, impacting the overall enzymatic turnover rate. Additionally, the inhibitor's structural motifs facilitate specific interactions with regulatory proteins, influencing cellular cycle progression. | ||||||
Cdk1/2 Inhibitor III | 443798-55-8 | sc-202530 | 1 mg | $198.00 | 3 | |
Cdk1/2 Inhibitor III demonstrates a distinctive binding affinity for Cdk2, characterized by its ability to form hydrogen bonds that enhance the stability of the enzyme-inhibitor complex. This compound disrupts the normal catalytic cycle by inducing conformational changes that hinder substrate access. Its unique reaction kinetics suggest a mixed inhibition model, affecting both substrate binding and catalytic efficiency. Furthermore, the inhibitor's structural features allow for selective modulation of protein-protein interactions, impacting downstream signaling pathways. | ||||||
BML-259 | 267654-00-2 | sc-202505 | 5 mg | $127.00 | 1 | |
BML-259 exhibits a remarkable selectivity for Cdk2, engaging in specific hydrophobic interactions that stabilize its binding. This compound alters the enzyme's active site geometry, effectively blocking substrate recognition and impeding phosphorylation processes. Its kinetic profile reveals a non-competitive inhibition mechanism, influencing the overall enzymatic turnover. Additionally, BML-259's unique structural motifs facilitate targeted disruption of regulatory networks, underscoring its role in cellular signaling modulation. | ||||||
R547 | 741713-40-6 | sc-364596 sc-364596A | 2 mg 5 mg | $375.00 $395.00 | ||
R547 is a selective CDK2 inhibitor that binds to the ATP-binding site, inhibiting substrate phosphorylation and leading to cell cycle arrest. | ||||||
PHA 767491 hydrochloride | 942425-68-5 | sc-204187 sc-204187A | 10 mg 50 mg | $194.00 $786.00 | 3 | |
PHA 767491 hydrochloride demonstrates a distinctive affinity for Cdk2, characterized by its ability to form hydrogen bonds with key amino acid residues within the enzyme's active site. This interaction leads to a conformational change that hinders substrate access, effectively reducing catalytic efficiency. The compound's unique electronic properties enhance its binding stability, while its specific steric configuration allows for selective interference in cell cycle regulation pathways, highlighting its intricate role in cellular dynamics. | ||||||